Figure 4From: The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials Forest plot for the aggregate proportion of patients who required dose reduction or cessation because of crizotinib toxicity in the treatment of locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Back to article page